Lymphocyte transglutaminase function may be impaired in type 2 diabetes mellitus.

Abstract

A method for capping of beta 2-microglobulin involving the transglutaminase inhibitor monodansylthiacadaverine was applied to lymphocytes from 17 patients with Type 2 diabetes mellitus and from a matched control group of 16 normoglycaemic healthy subjects. Monodansylthiacadaverine strongly inhibited the capping, which points to the involvement of transglutaminase in the redistribution of beta 2-microglobulin on the cell surface. The inhibition was more pronounced in lymphocytes from diabetic patients, indicating impaired transglutaminase function in Type 2 diabetes mellitus.

• Authors: E Berntorp, K Berntorp, B Seiving, P Stenberg
• Journal: Diabetes research (Edinburgh, Scotland) (Diabetes Res) Vol. 5 Issue 1 Pg. 29-33 (May 1987) ISSN: 0265-5985 [Print] Scotland
• PMID: 2887330 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• beta 2-Microglobulin
• monodansylthiacadaverine
• Transglutaminases
• Cadaverine
• Glipizide

Topics

• Cadaverine (analogs & derivatives, pharmacology)
• Diabetes Mellitus, Type 2 (enzymology)
• Glipizide (pharmacology)
• Humans
• Lymphocytes (enzymology)
• Male
• Middle Aged
• Receptor Aggregation (drug effects)
• Transglutaminases (antagonists & inhibitors, blood)
• beta 2-Microglobulin (metabolism)